.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Dow
McKesson
Novartis
QuintilesIMS
Teva
Farmers Insurance
Baxter
Cantor Fitzgerald
Merck

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206500

« Back to Dashboard

NDA 206500 describes VARUBI, which is a drug marketed by Tesaro Inc and is included in two NDAs. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the VARUBI profile page.

The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this compound. Additional details are available on the rolapitant hydrochloride profile page.

Summary for 206500

Tradename:1
Applicant:1
Ingredient:1
Patents:8

Suppliers and Packaging for NDA: 206500

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VARUBI rolapitant hydrochloride TABLET;ORAL 206500 NDA Tesaro, Inc. 69656-101 69656-101-02 2 TABLET in 1 BLISTER PACK (69656-101-02)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 90MG BASE
Approval Date:Sep 1, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 1, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Dec 8, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
Patent:► SubscribePatent Expiration:Apr 4, 2027Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Chubb
Chinese Patent Office
Novartis
Queensland Health
Moodys
Deloitte
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot